Pramipexole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Pramipexole
- Pramipexole: From Parkinson’s Disease to Attention-Deficit/Hyperactivity Disorder (ADHD)
Pramipexole: From Parkinson’s Disease to Attention-Deficit/Hyperactivity Disorder (ADHD)
One-Sentence Summary
Pramipexole is a non-ergot dopamine D2/D3 receptor agonist most established for Parkinson’s disease and restless legs syndrome. The TxGNN model predicts it may also be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), but current supporting evidence is limited to 1 clinical trial (not ADHD-specific) and 9 publications, most of which are case reports or mechanistic studies rather than dedicated ADHD trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s Disease (inferred from cited literature context; no formal India label text available — see Data Gap below) |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L4 (mechanistic studies and case reports; no dedicated ADHD RCT) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Pramipexole is not available in this evidence pack. Based on information found in the supporting literature, Pramipexole is a nonergoline compound with high selectivity for D3 dopamine receptors (PMID 19412489), and its efficacy in Parkinson’s disease and restless legs syndrome is well established through dopaminergic restoration.
ADHD pathophysiology is also linked to dopaminergic (and noradrenergic) dysregulation — one mechanistic study in the evidence set (PMID 34182128) specifically discusses dopamine D4 receptor polymorphisms and their association with ADHD, and a 2023 case report (PMID 37342213) describes symptom improvement when pramipexole was combined with atomoxetine in a patient with comorbid ADHD. These findings offer a plausible mechanistic rationale — dopamine agonism could theoretically modulate ADHD-related reward and attention circuits — but they are indirect, sparse, and not derived from disease-specific controlled trials.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00558766 | N/A | Completed | 35 | Studied motor cortex reward signaling in Parkinson’s disease patients using TMS, examining how dopaminergic medications affect compulsive/reward-related behavior. Not an ADHD therapeutic trial; included here for its dopaminergic reward-circuit relevance. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22407510 | 2012 | RCT | Movement Disorders | Multicenter placebo-controlled trial of pramipexole for Tourette’s syndrome, testing the dopamine-hypersensitivity hypothesis relevant to related dopaminergic disorders. |
| 24992083 | 2014 | RCT | Clinical Neuropharmacology | 11-week randomized trial comparing piribedil vs. pramipexole/ropinirole on vigilance and cognition in Parkinson’s disease patients with daytime sleepiness. |
| 18656214 | 2008 | Review | Revue Neurologique | Review of restless-legs syndrome pathophysiology and dopaminergic treatment context. |
| 19412489 | 2006 | Review | Neuropsychiatric Disease and Treatment | Reviews pramipexole’s D3-receptor selectivity and its repurposed use in restless legs syndrome. |
| 37342213 | 2023 | Case report | Frontiers in Pain Research | Remission of chronic low back pain and oral dysesthesia comorbid with ADHD following treatment with atomoxetine and pramipexole. |
| 38649244 | 2024 | Case report | BMJ Case Reports | Hypokalaemia case in a patient with ADHD, autism, and hypertension who was taking pramipexole among other medications (incidental mention, not a treatment study). |
| 15540638 | 2004 | Observational | Developmental Medicine & Child Neurology | Study of periodic leg movements in children with sleep disturbance, noting dopamine agonist (pramipexole) response. |
| 24079375 | 2013 | Preclinical | Journal of Motor Behavior | Animal model study proposing spontaneously hypertensive rats as a model linking RLS, periodic leg movements, and ADHD. |
| 34182128 | 2021 | Mechanistic | Pharmacological Research | Receptor pharmacology study on dopamine D4 receptor variants and their association with ADHD and impulse-control disorders. |
India Market Information
Pramipexole is currently not marketed in India per the available regulatory data, with no registration records on file.
Safety Considerations
Drug Interactions: A total of 142 interactions are on record. Notable moderate-level interactions include Morphine, Cimetidine, Dronabinol, Nabilone, Metoclopramide, Morphine (liposomal), and Opium. Minor-level interactions include Ranitidine and Ranitidine (bismuth citrate). A large number of additional interactions (e.g., Calcitriol, Pantoprazole, Glimepiride, Metformin, Omeprazole) are recorded with unclassified severity and should be reviewed individually before use.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but the ADHD-specific evidence base is weak — it consists of one non-therapeutic PD-related trial, a single relevant case report, and receptor-level mechanistic studies, with no dedicated ADHD clinical trial. Combined with the drug’s absence from the India market and zero existing registrations, the evidence does not yet support advancing this indication.
To proceed, the following is needed:
- Dedicated clinical trial or controlled study data evaluating Pramipexole specifically for ADHD
- Confirmed mechanism of action (MOA) documentation
- India-specific product labeling: approved indications, key warnings, and contraindications (currently unavailable — flagged as a blocking data gap)
- A regulatory pathway assessment given the drug has no existing India market presence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.